Cyteir: Stopping shape-shifters
Cyteir targets DNA repair enzyme critical for chronic lymphocytic leukemias
Cyteir Therapeutics Inc. is trying to curb the growth of chronic lymphocytic leukemia by blocking the repair of DNA damage. The company's small molecule hits a critical step in a DNA repair pathway that is overactive in about 40% of CLL patients.
DNA repair involves a series of enzymatic cuts and stitches to DNA molecules that become frayed as a result of mutation, radiation or chemically induced damage.
Many tumors spontaneously undergo rapid